{"id":6644,"date":"2024-11-21T13:57:14","date_gmt":"2024-11-21T12:57:14","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6644"},"modified":"2025-04-28T21:32:29","modified_gmt":"2025-04-28T19:32:29","slug":"a-highly-selective-pi3k%ce%b4-inhibitor-bgb-10188-shows-superior-preclinical-anti-tumor-activities-and-decreased-on-target-side-effects-on-colon","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/a-highly-selective-pi3k%ce%b4-inhibitor-bgb-10188-shows-superior-preclinical-anti-tumor-activities-and-decreased-on-target-side-effects-on-colon\/","title":{"rendered":"A highly selective PI3K\u03b4 inhibitor BGB-10188 shows superior preclinical anti-tumor activities and decreased on-target side effects on colon\u00a0"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6644","publication","type-publication","status-publish","hentry","disease_state-b-cell-malignancies","disease_state-hematologic-malignancies","molecule-zanubrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6644"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}